ROSEN Law Firm Encourages Corcept Therapeutics to Secure Counsel Before Deadline

Investors who purchased Corcept stock between October 2024 and December 2025 may be eligible for compensation.

Mar. 24, 2026 at 4:52am

Got story updates? Submit your updates here. ›

The ROSEN Law Firm, a global investor rights law firm, is reminding purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025 of the important April 21, 2026 lead plaintiff deadline in a securities class action lawsuit against the company. The lawsuit alleges that Corcept made misleading statements about the prospects of its drug relacorilant being approved by the FDA.

Why it matters

This case highlights the importance of transparency and accurate disclosures by public companies, especially regarding the status of regulatory approvals for their products. Investors rely on this information to make informed decisions, and any misleading statements can lead to significant losses.

The details

According to the lawsuit, Corcept represented that the clinical trials for relacorilant were strong support for the New Drug Application (NDA) submitted to the FDA, and that they were confident the NDA would be approved. However, the lawsuit claims the FDA had repeatedly raised concerns about the adequacy of the clinical evidence, creating a material risk that the NDA would not be approved.

  • The class period is from October 31, 2024 to December 30, 2025.
  • The lead plaintiff deadline is April 21, 2026.

The players

Corcept Therapeutics Incorporated

A pharmaceutical company that develops and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.

Rosen Law Firm

A global investor rights law firm that specializes in securities class actions and shareholder derivative litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel.”

— Laurence Rosen, Founding Partner, Rosen Law Firm

What’s next

Investors who purchased Corcept stock during the class period have until April 21, 2026 to move the court to serve as lead plaintiff in the class action lawsuit.

The takeaway

This case highlights the importance of transparency and accurate disclosures by public companies, especially regarding the regulatory approval process for their products. Investors should be cautious and thoroughly research any company they are considering investing in to ensure they are making informed decisions.